[Federal Register Volume 69, Number 189 (Thursday, September 30, 2004)]
[Notices]
[Page 58539]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-21949]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated May 21, 2004, and published in the Federal Register 
on June 3, 2004, (69 FR 31412), Cambrex North Brunswick, Inc., 
Technology Centre of New Jersey, 661 Highway One, North Brunswick, New 
Jersey 08902, made application by letter to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of 
Methadone (9250) and Methadone Intermediate (9254), basic classes of 
controlled substances listed in Schedule II.
    The company plans to manufacture the controlled substances for 
research and development purposes.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Cambrex North Brunswick, Inc. to manufacture the listed basic classes 
of controlled substances is consistent with the public interest at this 
time. DEA has investigated Cambrex North Brunswick, Inc. to ensure that 
the company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 
21 CFR 1301.33, the above named company is granted registration as a 
bulk manufacturer of the basic classes of controlled substances listed.

    Dated: September 8, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-21949 Filed 9-29-04; 8:45 am]
BILLING CODE 4410-09-M